{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,10,6]],"date-time":"2026-10-06T17:36:56Z","timestamp":1791308216374,"version":"4.3.1"},"reference-count":14,"publisher":"Oxford University Press (OUP)","issue":"5","license":[{"start":{"date-parts":[[2007,5,1]],"date-time":"2007-05-01T00:00:00Z","timestamp":1177977600000},"content-version":"vor","delay-in-days":0,"URL":"https:\/\/academic.oup.com\/journals\/pages\/open_access\/funder_policies\/chorus\/standard_publication_model"}],"content-domain":{"domain":[],"crossmark-restriction":false},"short-container-title":[],"published-print":{"date-parts":[[2007,5,1]]},"abstract":"<jats:sec>\n                    <jats:title>Learning Objectives<\/jats:title>\n                    <jats:p>After completing this course, the reader will be able to: Add panitumumab (Vectibix\u2122) to the armamentarium of drugs for colorectal cancer.Identify the patient group that is eligible for panitumumab therapy.Identify biologic agents that have activity in colorectal cancer.List the FDA criteria for the analysis of progression-free survival and for accelerated approval.<\/jats:p>\n                    <jats:p>CME Access and take the CME test online and receive 1 AMA PRA Category 1 Credit\u2122 at CME.TheOncologist.com<\/jats:p>\n                  <\/jats:sec>","DOI":"10.1634\/theoncologist.12-5-577","type":"journal-article","created":{"date-parts":[[2007,5,23]],"date-time":"2007-05-23T19:01:52Z","timestamp":1179946912000},"page":"577-583","source":"Crossref","is-referenced-by-count":185,"title":["FDA Drug Approval Summary: Panitumumab (Vectibix\u2122)"],"prefix":"10.1093","volume":"12","author":[{"given":"Ruthann M.","family":"Giusti","sequence":"first","affiliation":[{"name":"Office of Oncology Drug Products, Center for Drug Evaluation and Research, U.S. Food and Drug Administration, Silver Spring, Maryland, USA"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Kaushikkumar A.","family":"Shastri","sequence":"additional","affiliation":[{"name":"Office of Oncology Drug Products, Center for Drug Evaluation and Research, U.S. Food and Drug Administration, Silver Spring, Maryland, USA"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Martin H.","family":"Cohen","sequence":"additional","affiliation":[{"name":"Office of Oncology Drug Products, Center for Drug Evaluation and Research, U.S. Food and Drug Administration, Silver Spring, Maryland, USA"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Patricia","family":"Keegan","sequence":"additional","affiliation":[{"name":"Office of Oncology Drug Products, Center for Drug Evaluation and Research, U.S. Food and Drug Administration, Silver Spring, Maryland, USA"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Richard","family":"Pazdur","sequence":"additional","affiliation":[{"name":"Office of Oncology Drug Products, Center for Drug Evaluation and Research, U.S. Food and Drug Administration, Silver Spring, Maryland, USA"}],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"286","published-online":{"date-parts":[[2007,5,1]]},"reference":[{"key":"2021122208300783800_R1","doi-asserted-by":"crossref","first-page":"341","DOI":"10.1038\/nrc1609","article-title":"ERBB receptors and cancer: The complexity of targeted inhibitors","volume":"5","author":"Hynes","year":"2005","journal-title":"Nat Rev Cancer"},{"key":"2021122208300783800_R2","doi-asserted-by":"crossref","first-page":"195","DOI":"10.1146\/annurev.pharmtox.44.101802.121440","article-title":"ErbB receptors: Directing key signaling networks throughout life","volume":"44","author":"Holbro","year":"2004","journal-title":"Annu Rev Pharmacol Toxicol"},{"key":"2021122208300783800_R3","first-page":"165","article-title":"The biology of erbB-2\/neu\/HER-2 and its role in cancer","volume":"1198","author":"Hynes","year":"1994","journal-title":"Biochim Biophys Acta"},{"key":"2021122208300783800_R4","doi-asserted-by":"crossref","first-page":"177","DOI":"10.1126\/science.3798106","article-title":"Human breast cancer: Correlation of relapse and survival with amplification of the HER-2\/neu oncogene","volume":"235","author":"Slamon","year":"1987","journal-title":"Science"},{"key":"2021122208300783800_R5","doi-asserted-by":"crossref","first-page":"1229","DOI":"10.1517\/14712598.6.11.1229","article-title":"Panitumumab in colon cancer: A review and summary of ongoing trials","volume":"6","author":"Wainberg","year":"2006","journal-title":"Expert Opin Biol Ther"},{"key":"2021122208300783800_R6","doi-asserted-by":"crossref","first-page":"1010","DOI":"10.1634\/theoncologist.11-9-1010","article-title":"Challenges in the use of epidermal growth factor receptor inhibitors in colorectal cancer","volume":"11","author":"Van Cutsem","year":"2006","journal-title":"The Oncologist"},{"key":"2021122208300783800_R7","doi-asserted-by":"crossref","first-page":"1292","DOI":"10.1016\/j.ejca.2004.02.014","article-title":"Monoclonal antibodies in the treatment of colorectal cancer","volume":"40","author":"Veronese","year":"2004","journal-title":"Eur J Cancer"},{"key":"2021122208300783800_R8","volume-title":"Vectibix\u2122 (panitumumab)","author":"U.S. Food. Drug Administration","year":"2007"},{"key":"2021122208300783800_R9","doi-asserted-by":"crossref","first-page":"2335","DOI":"10.1056\/NEJMoa032691","article-title":"Bevacizumab plus irinotecan, fluorouracil, and leucovorin for metastatic colorectal cancer","volume":"350","author":"Hurwitz","year":"2004","journal-title":"N Engl J Med"},{"key":"2021122208300783800_R10","doi-asserted-by":"crossref","first-page":"60","DOI":"10.1200\/JCO.2003.10.066","article-title":"Phase II, randomized trial comparing bevacizumab plus fluorouracil (FU)\/leucovorin (LV) with FU\/LV alone in patients with metastatic colorectal cancer","volume":"21","author":"Kabbinavar","year":"2003","journal-title":"J Clin Oncol"},{"issue":"suppl 7","key":"2021122208300783800_R11","first-page":"13","article-title":"Targeting vascular endothelial growth factor in colorectal cancer","volume":"16","author":"Berlin","year":"2002","journal-title":"Oncology (Williston Park)"},{"key":"2021122208300783800_R12","doi-asserted-by":"crossref","first-page":"337","DOI":"10.1056\/NEJMoa033025","article-title":"Cetuximab monotherapy and cetuximab plus irinotecan in irinotecan-refractory metastatic colorectal cancer","volume":"351","author":"Cunningham","year":"2004","journal-title":"N Engl J Med"},{"key":"2021122208300783800_R13","doi-asserted-by":"crossref","first-page":"2005","DOI":"10.2165\/00003495-200666150-00011","article-title":"Panitumumab: In the treatment of metastatic colorectal cancer","volume":"66","author":"Hoy","year":"2006","journal-title":"Drugs"},{"key":"2021122208300783800_R14","author":"21 Code of Federal Regulations"}],"container-title":["The Oncologist"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/onlinelibrary.wiley.com\/doi\/pdf\/10.1634\/theoncologist.12-5-577","content-type":"application\/pdf","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/onlinelibrary.wiley.com\/doi\/full-xml\/10.1634\/theoncologist.12-5-577","content-type":"application\/xml","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/academic.oup.com\/oncolo\/article-pdf\/12\/5\/577\/41835032\/oncolo_12_5_577.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"syndication"},{"URL":"https:\/\/academic.oup.com\/oncolo\/article-pdf\/12\/5\/577\/41835032\/oncolo_12_5_577.pdf","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2021,12,22]],"date-time":"2021-12-22T09:24:34Z","timestamp":1640165074000},"score":1,"resource":{"primary":{"URL":"https:\/\/academic.oup.com\/oncolo\/article\/12\/5\/577\/6410477"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2007,5,1]]},"references-count":14,"journal-issue":{"issue":"5","published-online":{"date-parts":[[2007,5,1]]},"published-print":{"date-parts":[[2007,5,1]]}},"URL":"https:\/\/doi.org\/10.1634\/theoncologist.12-5-577","relation":{},"ISSN":["1083-7159","1549-490X"],"issn-type":[{"value":"1083-7159","type":"print"},{"value":"1549-490X","type":"electronic"}],"subject":[],"published-other":{"date-parts":[[2007,5,1]]},"published":{"date-parts":[[2007,5,1]]}}}